Join Growin Stock Community!

Cormedix inc.CRMD.US Overview

US StockHealthcare
(No presentation for CRMD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CRMD AI Insights

CRMD Overall Performance

CRMD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CRMD Recent Performance

0.07%

Cormedix inc.

0.05%

Avg of Sector

-0.31%

S&P500

CRMD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CRMD Key Information

CRMD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CRMD Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Price of CRMD

CRMD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CRMD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.06
PE Ratio (TTM)
3.23
Forward PE
7.93
PS Ratio (TTM)
2.62
PB Ratio
1.55
Price-to-FCF
7.55
METRIC
VALUE
vs. INDUSTRY
Gross Margin
92.61%
Net Margin
75.83%
Revenue Growth (YoY)
1647.67%
Profit Growth (YoY)
1836.85%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.06
PE Ratio (TTM)
3.23
Forward PE
7.93
PS Ratio (TTM)
2.62
PB Ratio
1.55
Price-to-FCF
7.55
Gross Margin
92.61%
Net Margin
75.83%
Revenue Growth (YoY)
1647.67%
Profit Growth (YoY)
1836.85%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
  • When is CRMD's latest earnings report released?

    The most recent financial report for Cormedix inc. (CRMD) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CRMD's short-term business performance and financial health. For the latest updates on CRMD's earnings releases, visit this page regularly.

  • Where does CRMD fall in the P/E River chart?

    According to historical valuation range analysis, Cormedix inc. (CRMD)'s current price-to-earnings (P/E) ratio is 5.54, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of CRMD?

    According to the latest financial report, Cormedix inc. (CRMD) reported an Operating Profit of 51.35M with an Operating Margin of 49.24% this period, representing a growth of 1,661.93% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CRMD's revenue growth?

    In the latest financial report, Cormedix inc. (CRMD) announced revenue of 104.28M, with a Year-Over-Year growth rate of 810.22%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CRMD have?

    As of the end of the reporting period, Cormedix inc. (CRMD) had total debt of 148.92M, with a debt ratio of 0.2. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CRMD have?

    At the end of the period, Cormedix inc. (CRMD) held Total Cash and Cash Equivalents of 48.49M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CRMD go with three margins increasing?

    In the latest report, Cormedix inc. (CRMD) achieved the “three margins increasing” benchmark, with a gross margin of 89.3%%, operating margin of 49.24%%, and net margin of 104.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CRMD's profit trajectory and future growth potential.

  • Is CRMD's EPS continuing to grow?

    According to the past four quarterly reports, Cormedix inc. (CRMD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.42. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CRMD?

    Cormedix inc. (CRMD)'s Free Cash Flow (FCF) for the period is 30.35M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 322.19% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CRMD?

    The latest valuation data shows Cormedix inc. (CRMD) has a Price-To-Earnings (PE) ratio of 5.54 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.